← Leaderboards
Shannon P Williams
Adenosine Therapeutics, Llc
$1,276,772
Attributed
$1,276,772
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $861.7K · FY2005–07$1M$750K$500K$250K$0
'05
'06
'07
Funding mix
By agency
NIH$1,565,049 · 4
By mechanism
R41$1,276,772 · 1
R44$288,277 · 3
Top collaborators
No co-investigators on record.
Most similar at Adenosine Therapeutics, Llc
Same institution · by research overlap
- Robert D Thompson$4,905,559
- George Allan Beller$2,554,046
- Robert A Figler$1,624,445
- Jayson Michael Rieger$2,043,625
- William M Scheld$633,055
Others in their field
Top investigators on “Acute Disease /Disorder”
- Barbara V Howard · Medlantic Research Institute$9,004,979
- John P Kinsella · University Of Colorado Denver$8,225,760
- Myron D Ginsberg · University Of Miami School Of Medicine$6,603,836
- William M Lee · University Of Texas Sw Med Ctr/Dallas$6,398,489
- Steven L. Wolf · Emory University$6,393,145
- M Christine Zink · Johns Hopkins University$6,105,094
Research focus
Acute Disease /DisorderAdenosineAdenosine A2a ReceptorAdministration, OralAdvanced DevelopmentAgonistAnimalsAntibiotic TherapyAnti-InflammatoryAnti-Inflammatory AgentsAntimicrobialBacteremiaBaseBioavailableBolus InfusionBusinessesCandida AlbicansCanis FamiliarisCardiacCardiovascular SystemChemokineClinically RelevantClinical Trial Phase IAcute
Grant awards (5)
Safety of Adenosine A2a Agonist for Treatment of Sepsis$415,035
R41 · FY2007 · AI · contact PI
Safety of A2A Adenosine Agonist for Treatment of Sepsis$861,737
R41 · FY2006 · AI · contact PI
A2a Adenosine Agonist Cardiac Reperfusion Injury$288,277
R44 · FY2005 · HL
Phase Ib: Study of ATL146e Employing the Human Endotoxin Model$0
R44 · FY2005 · HL
Phase II: Study of ATL146e in Patients Undergoing Primary Coronary Stenting$0
R44 · FY2005 · HL